“Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s117. doi:10.25251/skin.7.supp.117.